Essential thrombocythemia: challenges in clinical practice and future prospects

2.

Moulard

O

,

Mehta

J

,

Fryzek

J

, et al.

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union

.

Eur J Haematol

.

2014

;

92

(

4

):

289

-

297

.

3.

Verstovsek

S

,

Yu

J

,

Scherber

RM

, et al.

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States

.

Leuk Lymphoma

.

2022

;

63

(

3

):

694

-

702

.

4.

Grinfeld

J

,

Nangalia

J

,

Baxter

EJ

, et al.

Classification and personalized prognosis in myeloproliferative neoplasms

.

N Engl J Med

.

2018

;

379

(

15

):

1416

-

1430

.

5.

Mesa

RA

,

Miller

CB

,

Thyne

M

, et al.

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN landmark survey

.

Cancer

.

2017

;

123

(

3

):

449

-

458

.

6.

Harrison

CN

,

Koschmieder

S

,

Foltz

L

, et al.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey

.

Ann Hematol

.

2017

;

96

(

10

):

1653

-

1665

.

7.

Harrison

CN

,

Bareford

D

,

Butt

N

, et al.

Guideline for investigation and management of adults and children presenting with a thrombocytosis

.

Br J Haematol

.

2010

;

149

(

3

):

352

-

375

.

8.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

9.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

10.

Campbell

PJ

,

Scott

LM

,

Buck

G

, et al.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

.

Lancet

.

2005

;

366

(

9501

):

1945

-

1953

.

11.

Kittur

J

,

Knudson

RA

,

Lasho

TL

, et al.

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

.

Cancer

.

2007

;

109

(

11

):

2279

-

2284

.

12.

Nangalia

J

,

Massie

CE

,

Baxter

EJ

, et al.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

.

N Engl J Med

.

2013

;

369

(

25

):

2391

-

2405

.

13.

Elala

YC

,

Lasho

TL

,

Gangat

N

, et al.

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia

.

Am J Hematol

.

2016

;

91

(

5

):

503

-

506

.

14.

Vannucchi

AM

,

Antonioli

E

,

Guglielmelli

P

, et al.

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

.

Blood

.

2008

;

112

(

3

):

844

-

847

.

15.

Boyd

EM

,

Bench

AJ

,

Goday-Fernandez

A

, et al.

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis

.

Br J Haematol

.

2010

;

149

(

2

):

250

-

257

.

16.

Harrison

CN

,

Butt

N

,

Campbell

P

, et al.

Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia

.

Br J Haematol

.

2014

;

167

(

3

):

421

-

423

.

17.

Milosevic Feenstra

JD

,

Nivarthi

H

,

Gisslinger

H

, et al.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

.

Blood

.

2016

;

127

(

3

):

325

-

332

.

18.

Cabagnols

X

,

Favale

F

,

Pasquier

F

, et al.

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

.

Blood

.

2016

;

127

(

3

):

333

-

342

.

19.

Michail

O

,

McCallion

P

,

McGimpsey

J

, et al.

Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort

.

J Clin Pathol

.

2021

;

74

(

12

):

808

-

811

.

20.

Sirinukunwattana

K

,

Aberdeen

A

,

Theissen

H

, et al.

Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients

.

Blood Adv

.

2020

;

4

(

14

):

3284

-

3294

.

21.

Tefferi

A

,

Guglielmelli

P

,

Larson

DR

, et al.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

.

Blood

.

2014

;

124

(

16

):

2507

-

2513

.

22.

Sobas

M

,

Kiladjian

J-J

,

Beauverd

Y

, et al.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

.

Blood Adv

.

2022

;

6

(

17

):

5171

-

5183

.

23.

Passamonti

F

,

Rumi

E

,

Arcaini

L

, et al.

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

.

Haematologica

.

2008

;

93

(

11

):

1645

-

1651

.

24.

Barbui

T

,

Thiele

J

,

Passamonti

F

, et al.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study

.

J Clin Oncol

.

2011

;

29

(

23

):

3179

-

3184

.

25.

Abdulkarim

K

,

Ridell

B

,

Johansson

P

, et al.

The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera

.

Eur J Haematol

.

2011

;

86

(

2

):

148

-

155

.

26.

Campbell

PJ

,

Bareford

D

,

Erber

WN

, et al.

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

.

J Clin Oncol

.

2009

;

27

(

18

):

2991

-

2999

.

27.

Bjorkholm

M

,

Derolf

AR

,

Hultcrantz

M

, et al.

Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

.

J Clin Oncol

.

2011

;

29

(

17

):

2410

-

2415

.

28.

Loscocco

GG

,

Guglielmelli

P

,

Gangat

N

, et al.

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients

.

Am J Hematol

.

2021

;

96

(

11

):

1472

-

1480

.

29.

Tefferi

A

,

Lasho

TL

,

Guglielmelli

P

, et al.

Targeted deep sequencing in polycythemia vera and essential thrombocythemia

.

Blood Adv

.

2016

;

1

(

1

):

21

-

30

.

30.

Barbui

T

,

Vannucchi

AM

,

Buxhofer-Ausch

V

, et al.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

.

Blood Cancer J

.

2015

;

5

(

11

):

e369

.

31.

Tefferi

A

,

Guglielmelli

P

,

Lasho

TL

, et al.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

.

Br J Haematol

.

2020

;

189

(

2

):

291

-

302

.

32.

Cortelazzo

S

,

Viero

P

,

Finazzi

G

, et al.

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

.

J Clin Oncol

.

1990

;

8

(

3

):

556

-

562

.

33.

Besses

C

,

Cervantes

F

,

Pereira

A

, et al.

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

.

Leukemia

.

1999

;

13

(

2

):

150

-

154

.

34.

Barbui

T

,

Finazzi

G

,

Carobbio

A

, et al.

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

.

Blood

.

2012

;

120

(

26

):

5128

-

5133

. quiz 5252.

35.

Campbell

PJ

,

MacLean

C

,

Beer

PA

, et al.

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

.

Blood

.

2012

;

120

(

7

):

1409

-

1411

.

36.

Stein

BL

,

Martin

K

.

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms

.

Blood

.

2019

;

134

(

22

):

1902

-

1911

.

37.

Emanuel

RM

,

Dueck

AC

,

Geyer

HL

, et al.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

.

J Clin Oncol

.

2012

;

30

(

33

):

4098

-

4103

.

38.

Barbui

T

,

Tefferi

A

,

Vannucchi

AM

, et al.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

.

Leukemia

.

2018

;

32

(

5

):

1057

-

1069

.

39.

Alvarez-Larrán

A

,

Angona

A

,

Andrade-Campos

M

, et al.

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

.

Br J Haematol

.

2021

;

192

(

6

):

988

-

996

.

40.

Alvarez-Larrán

A

,

Sant’Antonio

E

,

Harrison

C

, et al.

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

.

Lancet Haematol

.

2021

;

8

(

9

):

e658

-

e665

.

41.

Alvarez-Larran

A

,

Pereira

A

,

Guglielmelli

P

, et al.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

.

Haematologica

.

2016

;

101

(

8

):

926

-

931

.

42.

Godfrey

AL

,

Campbell

PJ

,

MacLean

C

, et al.

Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features

.

J Clin Oncol

.

2018

;

36

(

34

):

3361

-

3369

.

43.

National Comprehensive Cancer Network

.

NCCN guidelines: myeloproliferative neoplasms, version 2, 2022.

. Accessed 15 August 2022. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf.

44.

Landolfi

R

,

Marchioli

R

,

Kutti

J

, et al.

Efficacy and safety of low-dose aspirin in polycythemia vera

.

N Engl J Med

.

2004

;

350

(

2

):

114

-

124

.

45.

Rocca

B

,

Tosetto

A

,

Betti

S

, et al.

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

.

Blood

.

2020

;

136

(

2

):

171

-

182

.

46.

Abraham

NS

,

Hlatky

MA

,

Antman

EM

, et al.

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents

.

Circulation

.

2010

;

122

(

24

):

2619

-

2633

.

47.

Cortelazzo

S

,

Finazzi

G

,

Ruggeri

M

, et al.

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

.

N Engl J Med

.

1995

;

332

(

17

):

1132

-

1136

.

48.

Barosi

G

,

Birgegard

G

,

Finazzi

G

, et al.

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

.

Blood

.

2009

;

113

(

20

):

4829

-

4833

.

49.

Hernández-Boluda

J-C

,

Alvarez-Larrán

A

,

Gómez

M

, et al.

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

.

Br J Haematol

.

2011

;

152

(

1

):

81

-

88

.

50.

Rumi

E

,

Pietra

D

,

Ferretti

V

, et al.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

.

Blood

.

2014

;

123

(

10

):

1544

-

1551

.

51.

Harrison

CN

,

Campbell

PJ

,

Buck

G

, et al.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

.

N Engl J Med

.

2005

;

353

(

1

):

33

-

45

.

52.

Barosi

G

,

Birgegard

G

,

Finazzi

G

, et al.

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

.

Br J Haematol

.

2010

;

148

(

6

):

961

-

963

.

53.

Birgegård

G

,

Besses

C

,

Griesshammer

M

, et al.

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study

.

Haematologica

.

2018

;

103

(

1

):

51

-

60

.

54.

Gisslinger

H

,

Gotic

M

,

Holowiecki

J

, et al.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

.

Blood

.

2013

;

121

(

10

):

1720

-

1728

.

55.

Ahn

IE

,

Natelson

E

,

Rice

L

.

Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide

.

Clin Lymphoma Myeloma Leuk

.

2013

;

13

(

suppl 2

):

S300

-

S304

.

56.

D’adda

M

,

Micheletti

M

,

Drera

M

,

Ferrari

S

,

Rossi

G

.

The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy

.

Leuk Lymphoma

.

2008

;

49

(

11

):

2216

-

2218

.

57.

Gugliotta

L

,

Besses

C

,

Griesshammer

M

, et al.

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study

.

Haematologica

.

2014

;

99

(

4

):

679

-

687

.

58.

Mascarenhas

J

,

Kosiorek

HE

,

Prchal

JT

, et al.

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

.

Blood

.

2022

;

139

(

19

):

2931

-

2941

.

59.

Yacoub

A

,

Mascarenhas

J

,

Kosiorek

H

, et al.

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

.

Blood

.

2019

;

134

(

18

):

1498

-

1509

.

60.

Desterro

J

,

McLornan

DP

,

Curto Garcia

N

, et al.

Essential thrombocythaemia treated with recombinant interferon: “real world” United Kingdom referral centre experience

.

Br J Haematol

.

2019

;

186

(

4

):

561

-

564

.

61.

Verger

E

,

Cassinat

B

,

Chauveau

A

, et al.

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

.

Blood

.

2015

;

126

(

24

):

2585

-

2591

.

62.

Mosca

M

,

Hermange

G

,

Tisserand

A

, et al.

Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms

.

Blood

.

2021

;

138

(

22

):

2231

-

2243

.

63.

Knudsen

TA

,

Skov

V

,

Stevenson

K

, et al.

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

.

Blood Adv

.

2022

;

6

(

7

):

2107

-

2119

.

64.

Gisslinger

H

,

Klade

C

,

Georgiev

P

, et al.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

.

Lancet Haematol

.

2020

;

7

(

3

):

e196

-

e208

.

65.

Verstovsek

S

,

Komatsu

N

,

Gill

H

, et al.

SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia

.

Future Oncol

.

2022

;

18

(

27

):

2999

-

3009

.

66.

Alvarez-Larrán

A

,

Martínez-Avilés

L

,

Hernández-Boluda

JC

, et al.

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

.

Ann Hematol

.

2014

;

93

(

12

):

2037

-

2043

.

67.

Begna

K

,

Abdelatif

A

,

Schwager

S

, et al.

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience

.

Blood Cancer J

.

2016

;

6

(

5

):

e427

.

68.

Douglas

G

,

Harrison

C

,

Forsyth

C

, et al.

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

.

Leuk Lymphoma

.

2017

;

58

(

1

):

89

-

95

.

69.

Renso

R

,

Aroldi

A

,

Pioltelli

P

,

Gambacorti-Passerini

C

,

Elli

EM

.

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea

.

Blood Cancer J

.

2018

;

8

(

6

):

56

.

70.

Verstovsek

S

,

Passamonti

F

,

Rambaldi

A

, et al.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

.

Blood

.

2017

;

130

(

15

):

1768

-

1771

.

71.

Harrison

CN

,

Mead

AJ

,

Panchal

A

, et al.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

.

Blood

.

2017

;

130

(

17

):

1889

-

1897

.

72.

Mascarenhas

J

,

Kremyanskaya

M

,

Patriarca

A

, et al.

BET inhibitor Pelabresib (CPI-0610) combined with Ruxolitinib in patients with myelofibrosis — JAK inhibitor-naïve or with suboptimal response to Ruxolitinib — preliminary data from the MANIFEST study

.

EHA Libr

.

2022

;

357062

:

S198

.

73.

Palandri

F

,

Ross

DM

,

Cochrane

T

, et al.

A phase 2 study of the LSD1 inhbitor IMG-7289 (Bomedemstat) for the treatment of essential thrombocythemia (ET)

.

EHA Libr

.

2022

;

357892

:

P1033

.

74.

Holmström

MO

,

Martinenaite

E

,

Ahmad

SM

, et al.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

.

Leukemia

.

2018

;

32

(

2

):

429

-

437

.

75.

Strickland

M

,

Quek

L

,

Psaila

B

.

The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy

.

Br J Haematol

.

2022

;

196

(

5

):

1149

-

1158

.

76.

Grinfeld

J

,

Godfrey

AL

.

After 10 years of JAK2V617F: disease biology and current management strategies in polycythaemia vera

.

Blood Rev

.

2017

;

31

(

3

):

101

-

118

.

77.

Randi

ML

,

Geranio

G

,

Bertozzi

I

, et al.

Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort

.

Br J Haematol

.

2015

;

169

(

4

):

584

-

589

.

78.

Baird

R

,

Banks

I

,

Cameron

D

, et al.

An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients

.

Ecancermedicalscience

.

2016

;

10

:

608

.

79.

Gangat

N

,

Wolanskyj

AP

,

Schwager

SM

,

Mesa

RA

,

Tefferi

A

.

Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia

.

Cancer

.

2006

;

106

(

11

):

2406

-

2411

.

80.

McMullin

MFF

,

Mead

AJ

,

Ali

S

, et al.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology Guideline

.

Br J Haematol

.

2019

;

184

(

2

):

161

-

175

.

81.

Alimam

S

,

Bewley

S

,

Chappell

LC

, et al.

Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study

.

Br J Haematol

.

2016

;

175

(

1

):

31

-

36

.

82.

Gangat

N

,

Joshi

M

,

Shah

S

, et al.

Pregnancy outcomes in myeloproliferative neoplasms: a Mayo clinic report on 102 pregnancies

.

Am J Hematol

.

2020

;

95

(

5

):

E114

-

E117

.

83.

Griesshammer

M

,

Struve

S

,

Harrison

CM

.

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe

.

Semin Thromb Hemost

.

2006

;

32

(

4 pt 2

):

422

-

429

.

84.

Robinson

SE

,

Harrison

CN

.

How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy

.

Br J Haematol

.

2020

;

189

(

4

):

625

-

634

.

85.

Kiladjian

JJ

,

Cervantes

F

,

Leebeek

FW

, et al.

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

.

Blood

.

2008

;

111

(

10

):

4922

-

4929

.

86.

Sant’Antonio

E

,

Guglielmelli

P

,

Pieri

L

, et al.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases

.

Am J Hematol

.

2020

;

95

(

2

):

156

-

166

.

87.

De Stefano

V

,

Vannucchi

AM

,

Ruggeri

M

, et al.

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients

.

Blood Cancer J

.

2016

;

6

(

11

):

e493

.

88.

De Stefano

V

,

Qi

X

,

Betti

S

,

Rossi

E

.

Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment

.

Thromb Haemost

.

2016

;

115

(

2

):

240

-

249

.

89.

Curto-Garcia

N

,

Doyle

AJ

,

Breen

KA

, et al.

Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK

.

Br J Haematol

.

2020

;

189

(

3

):

e79

-

e81

.

90.

Barbui

T

,

De Stefano

V

,

Carobbio

A

, et al.

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

.

Leukemia

.

2021

;

35

(

10

):

2989

-

2993

.

91.

Hamulyák

EN

,

Daams

JG

,

Leebeek

FWG

, et al.

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms

.

Blood Adv

.

2021

;

5

(

1

):

113

-

121

.

92.

Herbreteau

L

,

Papageorgiou

L

,

Le Clech

L

, et al.

Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms

.

Thromb Res

.

2022

;

216

:

25

-

34

.

93.

Ageno

W

,

Beyer Westendorf

J

,

Contino

L

, et al.

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study

.

Blood Adv

.

2022

;

6

(

12

):

3569

-

3578

.